title: [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
abstract: The antiemetic effect of granisetron on nausea and vomiting induced by cancer chemotherapy (CHOP, VEPA, VEPA-B, massive dose of ETP) was studied in fifty patients with non-Hodgkin's lymphoma. There was almost no difference in the inhibitory effect by regimen, with the rates of perfect inhibition of nausea and vomiting standing at 55.6% to 60%. Nausea and vomiting was perfectly controlled in 60% of 35 patients receiving CHOP therapy. As a part of this study, a comparison was made of perfect inhibitory effect on nausea and vomiting by potency of chemotherapy under the potency scale of 750 mg/m2 of CPA as 1, revealing no significant difference in the rates of complete inhibition as 71.4% for a drug potency of less than 0.8 vs 52.4% for 0.8 or above (p = 0.26). However, it was clear that the higher the dose of chemotherapy, the lower the rate of complete inhibition. The results confirmed the high efficacy and safety of granisetron in the treatment of nausea and vomiting induced by cancer chemotherapy.
authors.affiliation: Third Dept. of Internal Medicine, Kyoto Prefectural University of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Sasai
authors.forename: S
authors.initials: S
authors.lastname: Misawa
authors.forename: T
authors.initials: T
authors.lastname: Iwai
authors.forename: A
authors.initials: A
authors.lastname: Tamura
authors.forename: N
authors.initials: N
authors.lastname: Nakazawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ueda
authors.forename: H
authors.initials: H
authors.lastname: Kaneko
authors.forename: S
authors.initials: S
authors.lastname: Horiike
authors.forename: S
authors.initials: S
authors.lastname: Yokota
authors.forename: M
authors.initials: M
authors.lastname: Taniwaki
authors.forename: K
authors.initials: K
authors.lastname: Kashima
authors.forename: S
authors.initials: S
authors.lastname: Tsuda
authors.forename: Y
authors.initials: Y
authors.lastname: Ookawara
authors.forename: M
authors.initials: M
authors.lastname: Nakao
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: H
authors.initials: H
authors.lastname: Fujii
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D011241:Prednisone / Q000009:adverse effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D001761:Bleomycin; D003520:Cyclophosphamide; D004317:Doxorubicin; D005047:Etoposide; D017829:Granisetron; D011241:Prednisone; D012702:Serotonin Antagonists; D014750:Vincristine